<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
<channel>
	<title>BioToday.com [新着ニュース]</title>
	<description>BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。</description>
	<link>http://www.biotoday.com/news.cfm</link>
	<managingEditor>biotoday@biotoday.com</managingEditor>
	<copyright>Copyright &#169; 2026 BioToday Ltd. All Rights Reserved.</copyright>
	<lastBuildDate>Wed, 21 Oct 2026 14:47:02 +0900</lastBuildDate>
	<language>ja</language>
	<docs>http://blogs.law.harvard.edu/tech/rss</docs>
	<item>
		<title>[企業] AstraZenecaがOracleと協力して臨床試験の被験者が容易に見つかるようにする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110904&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110904&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 21 Oct 2026 14:47:02 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110904&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Gilead社のα4β7阻害薬emvistegrastがPh2試験で潰瘍性大腸炎患者の7割弱に奏効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110903&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110903&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 21 Oct 2026 13:37:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110903&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Rapport社のAMPA受容体抑制薬RAP-219が双極性躁病Ph2試験の目標達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110902&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110902&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 21 Oct 2026 13:06:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110902&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] GSKのB型肝炎薬Hibsagoを米国も承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110901&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110901&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 21 Oct 2026 10:19:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110901&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Amgen/AZのTezspireの好酸球性食道炎/EoE治療効果はDupixentに比肩するらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110900&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110900&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 21 Oct 2026 09:46:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110900&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 目当ての組織に治療手段を届ける脂質ナノ粒子開発でLillyがMETiS TechBioと提携</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110899&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110899&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 21 Oct 2026 08:23:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110899&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] GSKの抗PD-1抗体Jemperliの直腸癌治療を米国が取り急ぎ承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110898&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110898&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 16:55:06 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110898&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Veradermics社のミノキシジル経口薬のアンドロゲン性脱毛症Ph3試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110897&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110897&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 16:36:05 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110897&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Disc社の赤血球生成性プロトポルフィリン症薬bitopertinのPh3試験成功</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110896&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110896&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 15:46:44 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110896&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Merck KGaAがSilence社を13億ドルで買って真性多血症薬divesiranを手に入れる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110895&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110895&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 14:41:53 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110895&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AbbVieの手持ち2つ組み合わせのクローン病治療がそれら単独に比べて見栄えする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110894&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110894&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 14:06:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110894&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] フレームシフトペプチド癌ワクチンを開発するNouscom社が1億2千万ユーロ調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110893&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110893&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 12:50:41 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110893&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Rocheが癌治療ADCの開発で中国Hansoh社とさらに提携</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110892&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110892&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 10:17:14 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110892&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] SARS-CoV-2阻止二重特異性抗体複数を作るModerna社のmRNA薬がマウスで有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110891&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110891&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 09:49:38 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110891&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 急性腎障害の慢性腎疾患への進展にキノリン酸が寄与しているらしい</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110890&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110890&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Tue, 20 Oct 2026 07:18:27 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110890&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] Sanofiのアルツハイマー病薬SAR448851のマウスでの検討やPh1試験成績など</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110889&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110889&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 19 Oct 2026 16:24:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110889&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 慢性疾患や死にどれだけ近いかを示す老化の目安を2万人弱の代謝の記録から作成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110888&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110888&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 19 Oct 2026 15:42:39 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110888&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ホスファターゼPP2Aのヘテロ三量体を回復させる低分子薬が子宮癌マウスに有効</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110887&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110887&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 19 Oct 2026 15:06:12 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110887&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 肺胞幹細胞が肺胞の手入れのみならず気管支損傷の修復もする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110886&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110886&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 19 Oct 2026 12:28:36 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110886&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 【増補版】マイクロプラスチックが血液中で有害物質を生み出しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110885&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110885&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Mon, 19 Oct 2026 10:36:59 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110885&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] マイクロプラスチックが血液に入って有害物質を生み出しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110884&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110884&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 16:55:58 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110884&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 手術後の吐き気や嘔吐をノイズキャンセリングヘッドホン使用で減らせそう</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110883&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110883&amp;ref=rss</guid>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 16:39:26 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110883&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] City Therapeutics社が見込みを上回る2億ドルIPO調達を達成</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110882&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110882&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / IPO</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 15:53:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110882&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 米国FDAへの医療機器有害事象まとめ報告はしばしば不完全、不正確、遅ればせ</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110881&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110881&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 15:39:47 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110881&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ADPKD遺伝子治療を開発するEstuary社が1億ドルを手に発足</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110880&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110880&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資 || ビジネス / 会社運営 / 開業</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 13:31:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110880&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] NovartisのFabhaltaのループス腎炎Ph2試験中止</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110879&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110879&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 中止 || 開発 / 臨床試験 / 第2相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 11:33:03 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110879&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 老眼へのViatris社のフェントラミン点眼薬Ryzumvi使用を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110878&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110878&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 09:52:40 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110878&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] VerastemのKRAS阻害薬VS-7375が今年中に膵癌初治療Ph3試験に進む</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110877&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110877&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第1相試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Sun, 18 Oct 2026 08:19:09 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110877&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 甲状腺眼症へのRocheの抗IL-6薬Enspryng使用を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110876&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110876&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 16:46:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110876&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Galapagosで不要になったCAR-Tを同社の元CEO等が設立した新会社が引き取る</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110875&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110875&amp;ref=rss</guid>
		<category>ビジネス / 会社運営 / 開業</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 16:39:58 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110875&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] OrbiMedが米国、欧州、アジアへの医療投資資金30億ドルを預かり</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110874&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110874&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 15:25:51 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110874&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] AstraZenecaがinsitro社と組んで脂肪肝や心筋症の狙い目や治療を探す</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110873&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110873&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 14:49:27 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110873&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] LillyのOmvohでIBD患者の少なくとも2割ほどがより完膚なき寛解を達成しうる</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110872&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110872&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 13:51:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110872&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] OMass社が副腎疾患薬OMS1620のPh2試験資金3億1000万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110871&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110871&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 10:02:24 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110871&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] ヒト並み言語能力を有するAIの試験の公表がどれだけ指針に沿っているかを検討</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110870&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110870&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 09:38:35 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110870&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Vanda社のα7-nAChR部分活性化薬VQW-765の社交不安症Ph3試験失敗</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110869&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110869&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 08:40:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110869&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ImmunityBio社の膀胱癌治療IL-15受容体活性化薬Anktivaの用途拡大を米国承認</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110868&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110868&amp;ref=rss</guid>
		<category>開発 / 承認申請 / 承認取得</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Fri, 16 Oct 2026 08:17:23 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110868&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 妊娠前HPVワクチン接種と早産を生じ難いことが関連</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110867&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110867&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 16:48:31 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110867&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 膝/股関節置換のどちらでもロボット手術の取り柄なし</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110866&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110866&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 16:24:33 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110866&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] いまどきの閉経期ホルモン経口薬使用と静脈血栓塞栓を生じ易いことが関連</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110865&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110865&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 14:27:57 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110865&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 抗うつ薬開始後早々の心血管一大事の増加なし</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110864&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110864&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 13:20:18 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110864&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Gilead社の癌治療T細胞差し向け薬作りにVir Biotechnologyが協力する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110863&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110863&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 12:23:00 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110863&amp;ref=rss</comments>
	</item>
	<item>
		<title>[医学] 透析患者への死者からの腎臓移植は定番基準なら透析継続に比べて生存を延長</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110862&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110862&amp;ref=rss</guid>
		<category>ジャーナル / 総合医学誌 / BMJ</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 11:29:32 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110862&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Liquidia社が特許訴訟裁判での敗北を受けて4億ドル弱をUnited社に払う</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110861&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110861&amp;ref=rss</guid>
		<category>ビジネス / トラブル / 訴訟</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 10:08:17 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110861&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 筋ジストロフィー経口薬のPh1/2試験資金3700万ドルをAltay社が調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110860&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110860&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 08:46:31 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110860&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] 肝臓に囚われず目指す細胞に届くsiRNA治療のUndecimal Bio社が2千万ドル弱調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110859&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110859&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資 || ビジネス / 会社運営 / 開業</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 08:19:11 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110859&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] ZealandがGenerateのAI込み技術を使って肥満治療蛋白質を設計する</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110858&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110858&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 企業間提携</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Thu, 15 Oct 2026 07:27:15 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110858&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Ph1/2試験段階のFSHD薬SFL-0821を擁するSouffle社が1億3500万ドル調達</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110857&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110857&amp;ref=rss</guid>
		<category>ビジネス / ファイナンス / 投資/融資</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 14 Oct 2026 16:37:43 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110857&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] Paragon社下請け9つ目のVelarisをAlaunosが買って肺高血圧症開発品を手にする</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110856&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110856&amp;ref=rss</guid>
		<category>ビジネス / 対外交渉 / 合併/買収</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 14 Oct 2026 15:06:08 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110856&amp;ref=rss</comments>
	</item>
	<item>
		<title>[企業] BioNTechのHPV標的mRNA癌ワクチンPh2/3試験で無増悪生存（PFS）改善ならず</title>
		<description></description>
		<link>http://www.biotoday.com/view.cfm?n=110855&amp;ref=rss</link>
		<guid>http://www.biotoday.com/view.cfm?n=110855&amp;ref=rss</guid>
		<category>開発 / 臨床試験 / 第3相/ピボタル試験</category>
		<author>biotoday@biotoday.com</author>
		<pubDate>Wed, 14 Oct 2026 14:35:22 +0900</pubDate>
		<comments>http://www.biotoday.com/post_comment.cfm?init=A110855&amp;ref=rss</comments>
	</item>
</channel>
</rss>
